Peter Attia's latest podcast episode argues that peptides are real drugs requiring individual evaluation through a five-question framework and a three-tier evidence classification revised from his earlier AMA episodes. The episode applies the framework to BPC-157 and CJC-1295, both of which lack…
Peter Attia has released an episode of The Peter Attia Drive podcast built around a single argument: peptides are real drugs and must be evaluated as such, individually, through a standardized framework and explicit evidence tiers. The episode condenses the framework Attia first presented in AMA #83 into a more accessible form, introduces a three-tier evidence classification revised from the original four buckets, and applies it to BPC-157 and CJC-1295, two of the most widely marketed peptides in the wellness gray market. It also takes on common marketing claims and the risks of buying unapproved molecules outside the regulated drug supply.
The episode's first move is to retire the category question. "The word tells you almost nothing about whether a molecule is safe, effective, or even scientifically plausible," Attia says. "Peptide" is a chemical description covering molecules of wildly different sizes, targets, potencies, and half-lives; it is not a mark of quality or safety. That distinction frames the entire episode, which treats the search for a single verdict on "peptides" as a category error.
What is new is the packaging. Regular listeners will recognize the underlying position from AMA #83, but the new episode reorganizes it around a five-question checklist, a three-tier evidence scale, and worked examples. For someone deciding whether to use a peptide, the episode functions as a decision procedure rather than a verdict.
Attia says the common question, "Do peptides work?", is the wrong one. "You're asking the wrong question," he says. "Rather than ask one simple question, whether peptides work, we actually need to be asking multiple specific questions about individual peptides."
The framework consists of five questions that apply to any drug: Does the molecule have a viable mechanism of action? Is there evidence of meaningful benefit in humans? Are safety, dosing, and pharmacokinetics adequately characterized? Is the risk-benefit balance acceptable in context? And does a better-characterized alternative already exist? "If you're putting something into your body, I think these are the questions worth asking," Attia says. The questions are deliberately uniform, so that a drug the user already favors faces the same scrutiny as one they distrust.
The evidence classification is the second structural element. Attia now sorts peptides into three tiers: scientifically unsupported; biologically plausible but lacking human clinical evidence; and, implicitly, supported by evidence. The three-tier scheme revises the four buckets used in the earlier AMA #83 episode, which the new episode references as the source of the framework throughout. The segment defining peptides and explaining why they must be evaluated individually opens at 3:15 in the audio and at 0:11 in the video edition.
The scientific core of the argument is that a molecule's marketability and its biology are separate things. Most marketed peptides, Attia points out, are synthetic, deliberately modified versions of natural molecules, engineered for tighter receptor binding, longer duration of action, or novel targets. Those modifications make each compound a unique drug rather than a representative of a class, and they make reasoning by analogy unsafe. A peptide that resembles a natural hormone in name may differ from it substantially in behavior.
Mechanism matters because it makes claims falsifiable. A defined mechanism lets a researcher specify what should happen if the hypothesis is correct and identify failure modes when it is not: poor tissue penetration, rapid degradation, off-target effects, or biomarker changes that occur without any corresponding clinical effect. Without a defined mechanism, a claim is nearly impossible to test, which is why the episode treats unexplained mechanisms as an early red flag.
The base rates argue for skepticism. Only about 3% of FDA-approved drugs have genuinely unclear mechanisms of action, so mystery mechanisms are the exception in approved medicine, not the rule. And roughly 30-50% of drugs that clear preclinical testing and enter phase 1 trials never advance to phase 2, because they do not behave in humans as anticipated. The implication is direct: if half of carefully developed drugs fail the transition from animals to humans, an unstudied gray-market peptide cannot claim a presumption of efficacy.
Peptide Atlas's own files illustrate the gap between marketing and evidence. BPC-157, one of the most heavily marketed peptides in the wellness space, has one registered clinical trial on file. The trial, NCT07437547, is a phase 2 study of BPC-157 for acute hamstring muscle strain repair with a status of recruiting; it has produced no results. The compound's indexed PubMed literature is larger, at 105 papers, but the recent record is dominated by animal work and reviews. A May 2026 paper in Scientific Reports reports protective effects of BPC-157 in rats with lower extremity ischemia-reperfusion injury. A March 2026 Current Neuropharmacology paper describes BPC-157 in severe electrolyte disturbances in rats. A May 2026 Pharmaceutics review catalogues the compound's biopharmaceutical challenges, formulation strategies, and translational development barriers. There is a genuine preclinical footprint, and almost no human clinical footprint.
The purity data on file does not close the gap. Peptide Atlas holds 10 third-party lab purity tests for BPC-157, with the highest observed purity at 99.878%. A high purity reading tells a buyer that the vial contains what the label claims. It says nothing about whether the molecule works in humans, what dose is appropriate, or what the risks are. That is exactly the distinction Attia's framework draws between answering a chemistry question and answering the drug questions.
CJC-1295 is the more striking case. Peptide Atlas has zero registered clinical trials on file for the compound and only 7 indexed PubMed papers. The recent literature skews toward detection and sports contexts: a March 2026 doping review in the Journal of Sports Medicine and Physical Fitness on peptide use in sport and bodybuilding, a January 2026 method for analyzing growth hormone releasing hormone and its analogs in urine by nano liquid chromatography with quadrupole/orbitrap mass spectrometry, and a 2019 method for confirming CJC-1295 abuse in equine plasma. The compound shows biological activity, but no registered trial tests whether that activity produces meaningful clinical benefit.
These records map closely onto the episode's assessments. BPC-157, in the episode's telling, has unclear mechanisms, absent human evidence, and unknown risks despite expanding claims. CJC-1295 shows biological activity but lacks evidence of meaningful clinical benefit. Under the three-tier scheme, CJC-1295 is the clearest case of biologically plausible without human evidence. BPC-157 sits in a more fragile position: an unclear mechanism leaves it short of the biological plausibility standard even before the absence of human data is considered.
The episode is explicit about which sources of reassurance do not count. Testimonials cannot establish effectiveness because of the placebo effect; controlled trials are necessary. Prescriptions from doctors, the use of compounding pharmacies, and third-party testing do not validate an unapproved peptide. FDA approval provides a benchmark for evaluating peptide safety and effectiveness, and the episode treats its absence as substantive rather than procedural.
Gray-market logic matters for clinicians. A patient's "BPC-157" may come from any of dozens of suppliers with different synthesis routes, purity profiles, and dosage forms. Evidence for an approved peptide does not automatically extend to gray-market versions of the same molecule, because sourcing and quality control differ. The episode's position is that evidence should precede widespread use rather than be expected to catch up later.
The episode also addresses the claim that pharmaceutical companies ignore natural peptides because they cannot be patented. Whatever the merits of that explanation for commercial neglect, it does not bear on the questions that matter. A molecule that cannot be patented can still be characterized, studied in controlled trials, and evaluated for safety and dosing. Patent status explains why a product is marketed by supplement companies rather than developed by drug companies; it does not establish that the product works.
Attia does not describe the people using these products as reckless. He describes them as hopeful, and the episode's concern is that "hope has become a product," with extraordinary claims attached to molecules that have not earned them. The framework is designed to remove personal bias by forcing the same questions for all drugs, including those the user favors or disfavors. Risk, in the episode's framing, is contextual: a serious adverse effect may be acceptable for a lethal childhood disease but unacceptable for a marginal wellness benefit.
The framework is a tool, not a dataset. It does not say which peptides belong in the supported evidence tier, which compounds in the biologically plausible tier will ever generate human data, or how the gray market should be regulated. The most immediate open question is definitional: what precisely defines the third tier, and which peptides qualify for it?
The evidence gaps are concrete and testable. No specific clinical outcome studies for CJC-1295 are registered, so whether its biological activity translates into benefit has no answer yet. For BPC-157, animal and mechanistic studies exist, including the ischemia-reperfusion and electrolyte disturbance work in rats, but none have advanced to completed human trials. The single registered phase 2 trial, still recruiting, is the only clinical test on record.
For clinicians, the unresolved question is practical: how to counsel patients who are using or considering gray-market peptides, when the products are legal to buy, unapproved as drugs, and largely unstudied. For regulators, the question is institutional: what enforcement or policy changes could address an industry that sells injection-grade molecules outside the drug approval process. The framework makes the evidentiary standard clear, but it does not by itself create the trials, the data, or the enforcement that the standard demands.
Peptides referenced: BPC-157, CJC-1295, Growth Hormone.
Related reading: Craft Health’s CraftMake Platform Gets a Peptide Test Run - 3D Printing Industry, Three biotechs with three news updates, Qnovia licenses novel antimicrobial peptide, The Best Peptide Beauty Products for Firmer, Hydrated Skin, According to Dermatologists.